SGLT2 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers In-Depth Analysis of Global SGLT2 Meds & Dapagliflozin Market Size. The SGLT2 Inhibitors Market is Segmented Into Drug (Invokana, Jardiance, Farxiga/forxiga, And Suglat) and Geography. The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

SGLT2 Inhibitors Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

SGLT2 Inhibitors Market Size

Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 12.41 Billion
Market Size (2030) USD 18.82 Billion
CAGR (2025 - 2030) 8.68 %
Fastest Growing Market Middle East and North Africa
Largest Market North America
Market Concentration High

Major Players

Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

SGLT2 Inhibitors Market Analysis

The Sodium-dependent Glucose Co-transporter 2 Market size is estimated at USD 12.41 billion in 2025, and is expected to reach USD 18.82 billion by 2030, at a CAGR of 8.68% during the forecast period (2025-2030).

The Sodium-Dependent Glucose Cotransporter 2 market benefited from the COVID-19 pandemic. People with diabetes have a weakened immune system, which is exacerbated by COVID-19. Diabetes patients are more likely than non-diabetics to have significant problems. Diabetic medicine makers took care during COVID-19 to ensure that pharmaceuticals were delivered to diabetes patients with the assistance of local governments. 

"Since the start of COVID-19, our commitment to patients, our employees, and the communities where we operate has remained unchanged," NovoNordisk stated on their website. "We continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19."

SGLT-2 inhibitors, commonly known as gliflozins, are a kind of medication used to treat type 2 diabetes by lowering high blood glucose levels. SGLT-2 inhibitors have an important role in the management of cardiovascular risk factors such as blood pressure, glycemia, weight, cardiac function, and antiinflammatory action. Diabetic medications have been proposed as prospective treatments for diabetic people infected with SARS-CoV-2 during the COVID-19 epidemic. Technological advancements have increased over the period leading to several modifications either in the SGLT-2 inhibitors or the formulations being developed.

Therefore, due to increased prevalence and the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.

SGLT2 Inhibitors Industry Overview

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is highly consolidated, with a few significant manufacturers having a global market presence. The companies strengthen their market presence by getting approval in new forms.

SGLT2 Inhibitors Market Leaders

  1. Janssen Pharmaceuticals

  2. Eli Lilly

  3. Bristol Myers Squibb

  4. AstraZeneca Pharmaceuticals

  5. Astellas

  6. *Disclaimer: Major Players sorted in no particular order
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

SGLT2 Inhibitors Market News

  • June 2023: the U.S. Food and Drug Administration approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes. These approvals provide a new class of medicines taken by mouth to treat pediatric type 2 diabetes. 
  • April 2022: Nippon Boehringer Ingelheim's SGLT-2 inhibitor Jardiance (empagliflozin) obtained a label update from PMDA in Japan, allowing its use in patients with chronic heart failure with preserved ejection fraction (HFpEF) in addition to those with heart failure with reduced ejection fraction (HFrEF).

SGLT2 Inhibitors Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Sodium - Glucose Co-transport -2 (SGLT-2) Inhibitor
    • 5.1.1.1 Invokana (Canagliflozin)
    • 5.1.1.2 Jardiance (Empagliflozin)
    • 5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
    • 5.1.1.4 Suglat (Ipragliflozin)
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Rest of North America
    • 5.2.2 Europe
    • 5.2.2.1 France
    • 5.2.2.2 Germany
    • 5.2.2.3 Italy
    • 5.2.2.4 Spain
    • 5.2.2.5 United Kingdom
    • 5.2.2.6 Russia
    • 5.2.2.7 Rest of Europe
    • 5.2.3 Latin America
    • 5.2.3.1 Mexico
    • 5.2.3.2 Brazil
    • 5.2.3.3 Rest of Latin America
    • 5.2.4 Asia-Pacific
    • 5.2.4.1 Japan
    • 5.2.4.2 South Korea
    • 5.2.4.3 China
    • 5.2.4.4 India
    • 5.2.4.5 Australia
    • 5.2.4.6 Vietnam
    • 5.2.4.7 Malaysia
    • 5.2.4.8 Indonesia
    • 5.2.4.9 Philippines
    • 5.2.4.10 Thailand
    • 5.2.4.11 Rest of Asia-Pacific
    • 5.2.5 Middle-East and Africa
    • 5.2.5.1 Saudi Arabia
    • 5.2.5.2 Iran
    • 5.2.5.3 Egypt
    • 5.2.5.4 Oman
    • 5.2.5.5 South Africa
    • 5.2.5.6 Rest of Middle-East and Africa

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Eli Lilly
    • 7.1.2 Janssen Pharmaceuticals
    • 7.1.3 Bristol Myers Squibb
    • 7.1.4 Boehringer Ingelheim
    • 7.1.5 AstraZeneca
    • 7.1.6 Astellas
  • *List Not Exhaustive
  • 7.2 MARKET SHARE ANALYSIS
    • 7.2.1 Eli Lilly
    • 7.2.2 Janssen Pharmaceuticals
    • 7.2.3 Astellas
    • 7.2.4 Boehringer Ingelheim
    • 7.2.5 AstraZeneca

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents. **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

SGLT2 Inhibitors Industry Segmentation

A family of glucose transporters is known as sodium-dependent glucose co-transporters (also known as sodium-glucose linked transporters or SGLT2). Only the proximal renal tubules express it, which is responsible for 90% of glucose reabsorption from tubular fluid. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is segmented into drugs (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography. The report offers the value (in USD) and volume (in Units) for the above segments. 

Drug Sodium - Glucose Co-transport -2 (SGLT-2) Inhibitor Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Geography North America United States
Canada
Rest of North America
Europe France
Germany
Italy
Spain
United Kingdom
Russia
Rest of Europe
Latin America Mexico
Brazil
Rest of Latin America
Asia-Pacific Japan
South Korea
China
India
Australia
Vietnam
Malaysia
Indonesia
Philippines
Thailand
Rest of Asia-Pacific
Middle-East and Africa Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle-East and Africa
Need A Different Region or Segment?
Customize Now

SGLT2 Inhibitors Market Research FAQs

How big is the Sodium-dependent Glucose Co-transporter 2 Market?

The Sodium-dependent Glucose Co-transporter 2 Market size is expected to reach USD 12.41 billion in 2025 and grow at a CAGR of 8.68% to reach USD 18.82 billion by 2030.

What is the current Sodium-dependent Glucose Co-transporter 2 Market size?

In 2025, the Sodium-dependent Glucose Co-transporter 2 Market size is expected to reach USD 12.41 billion.

Who are the key players in Sodium-dependent Glucose Co-transporter 2 Market?

Janssen Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, AstraZeneca Pharmaceuticals and Astellas are the major companies operating in the Sodium-dependent Glucose Co-transporter 2 Market.

Which is the fastest growing region in Sodium-dependent Glucose Co-transporter 2 Market?

Middle East and North Africa is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Sodium-dependent Glucose Co-transporter 2 Market?

In 2025, the North America accounts for the largest market share in Sodium-dependent Glucose Co-transporter 2 Market.

What years does this Sodium-dependent Glucose Co-transporter 2 Market cover, and what was the market size in 2024?

In 2024, the Sodium-dependent Glucose Co-transporter 2 Market size was estimated at USD 11.33 billion. The report covers the Sodium-dependent Glucose Co-transporter 2 Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Sodium-dependent Glucose Co-transporter 2 Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

SGLT2 Drugs Industry Report

Statistics for the 2025 Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.